
1373TiPILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Butler, M O, Robert, C, Negrier, S, In, G K, Walker, J, Krajsova, I, Atkinson, V G, Hansson, J, Kapiteijn, E, Loquai, C, Shaw, H M, Cheng, T, Mansard, S, Grob, J J, Guidoboni, M, Mehta, M, Ascierto, PVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz255.061
Date:
October, 2019
Fichier:
PDF, 96 KB
2019